115 related articles for article (PubMed ID: 37351957)
1. Association Between 18F-Fluorodeoxyglucose Uptake and Mutation Status of Epidermal Growth Factor Receptor in Sinonasal Tract Cancer.
Suzuki H; Sasaki E; Tamaki T; Kodaira T; Nishio M; Nishikawa D; Beppu S; Terada H; Sawabe M; Hanai N
Anticancer Res; 2023 Jul; 43(7):3247-3253. PubMed ID: 37351957
[TBL] [Abstract][Full Text] [Related]
2. [Value of (18)F-FDG PET-CT imaging to predict epidermal growth factor receptor mutations in patients with lung squamous cell carcinoma].
Zhao CY; Deng XY; Wang HS; Cao GP; Ding JN; Ding CY
Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):795-800. PubMed ID: 34289575
[No Abstract] [Full Text] [Related]
3. The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations.
Wumener X; Zhang Y; Zang Z; Du F; Ye X; Zhang M; Liu M; Zhao J; Sun T; Liang Y
BMC Pulm Med; 2024 May; 24(1):227. PubMed ID: 38730287
[TBL] [Abstract][Full Text] [Related]
4. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
Mak RH; Digumarthy SR; Muzikansky A; Engelman JA; Shepard JA; Choi NC; Sequist LV
Oncologist; 2011; 16(3):319-26. PubMed ID: 21339258
[TBL] [Abstract][Full Text] [Related]
5. [Semiquantitative parameters of
Liao XH; Wang RF; Liu M; Chen XQ; Xiong Y; Nong L; Yin L; Zhang BY; DU YJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 53(2):246-254. PubMed ID: 33879893
[TBL] [Abstract][Full Text] [Related]
6. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y
Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography/CT volume-based parameters in patients with oropharyngeal squamous cell carcinoma with known p16 and p53 status.
Kikuchi M; Koyasu S; Shinohara S; Usami Y; Imai Y; Hino M; Itoh K; Tona R; Kanazawa Y; Kishimoto I; Harada H; Naito Y
Head Neck; 2015 Oct; 37(10):1524-31. PubMed ID: 24890445
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of
Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
[TBL] [Abstract][Full Text] [Related]
9. Correlation between EGFR mutation status and F
Zhu L; Yin G; Chen W; Li X; Yu X; Zhu X; Jiang W; Jia C; Chen P; Zhang Y; Lu D; Yu L; Li X; Xu W
Thorac Cancer; 2019 Apr; 10(4):659-664. PubMed ID: 30776196
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
Wang D; Zhang M; Gao X; Yu L
PLoS One; 2016; 11(6):e0158307. PubMed ID: 27336755
[TBL] [Abstract][Full Text] [Related]
11. The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status.
Moan JM; Amdal CD; Malinen E; Svestad JG; Bogsrud TV; Dale E
Radiother Oncol; 2019 Nov; 140():54-61. PubMed ID: 31177043
[TBL] [Abstract][Full Text] [Related]
12. Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
Ko KH; Hsu HH; Huang TW; Gao HW; Shen DH; Chang WC; Hsu YC; Chang TH; Chu CM; Ho CL; Chang H
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1889-97. PubMed ID: 24852187
[TBL] [Abstract][Full Text] [Related]
13. [Evaluate the value of (18)F-FDG PET-CT imaging in predicting the mutationsin epidermal growth factor receptor in lung adenocarcinoma].
Ding CY; Yang WP; Guo Z; Sun J; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):528-531. PubMed ID: 28728300
[No Abstract] [Full Text] [Related]
14. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer.
Liu A; Han A; Zhu H; Ma L; Huang Y; Li M; Jin F; Yang Q; Yu J
Oncotarget; 2017 May; 8(20):33736-33744. PubMed ID: 28422710
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of multiple metabolic and heterogeneity parameters of
Shi A; Wang J; Wang Y; Guo G; Fan C; Liu J
Ann Nucl Med; 2022 Apr; 36(4):393-400. PubMed ID: 35084711
[TBL] [Abstract][Full Text] [Related]
16. Primary metabolic tumor volume from 18F-FDG PET/CT associated with epidermal growth factor receptor mutation in lung adenocarcinoma patients.
Liao X; Cui Y; Chen X; Di L; Tong Z; Liu M; Wang R
Nucl Med Commun; 2020 Nov; 41(11):1210-1217. PubMed ID: 32815896
[TBL] [Abstract][Full Text] [Related]
17. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
18. Effect of Epidermal Growth Factor Receptor Mutation on Positron Emission Tomography/Computed Tomography in Lung Cancer.
Park JS; Park HY; Choi Y
Anticancer Res; 2024 Jun; 44(6):2681-2687. PubMed ID: 38821597
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with
Risør LM; Clausen MM; Ujmajuridze Z; Farhadi M; Andersen KF; Loft A; Friborg J; Kjaer A
J Nucl Med; 2022 Aug; 63(8):1169-1176. PubMed ID: 34857658
[TBL] [Abstract][Full Text] [Related]
20. Relation of EGFR Mutation Status to Metabolic Activity in Localized Lung Adenocarcinoma and Its Influence on the Use of FDG PET/CT Parameters in Prognosis.
Kim YI; Paeng JC; Park YS; Cheon GJ; Lee DS; Chung JK; Kang KW
AJR Am J Roentgenol; 2018 Jun; 210(6):1346-1351. PubMed ID: 29547059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]